Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
Jpn J Clin Oncol
; 54(2): 221-224, 2024 Feb 07.
Article
em En
| MEDLINE
| ID: mdl-37886853
ABSTRACT
New approaches involving immune checkpoint inhibitors and antibody-drug conjugates prolong overall survival in patients with metastatic urothelial carcinoma. However, the access to such systemic therapy in clinical practice is suboptimal, and whether these agents improve overall survival in patients with metastatic urothelial carcinoma over time remains unclear. Hence, we investigated the overall survival trend from the initiation of first-line therapy with these agents to identify changes due to the medication and time of treatment initiation. We retrospectively evaluated 195 patients from a single center. They were treated with chemotherapy, pembrolizumab, or avelumab or enfortumab vedotin. The treatment was categorized into chemotherapy, pembrolizumab or avelumab/enfortumab vedotin period. The new agents prolonged overall survival from the start of first-line therapy. Furthermore, sequential treatment with these agents in real-world clinical practice has been reported to prolong overall survival. These study results will have major implications when a new first-line therapy is approved in the future.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Imunoconjugados
/
Antineoplásicos Imunológicos
Limite:
Humans
Idioma:
En
Revista:
Jpn J Clin Oncol
Ano de publicação:
2024
Tipo de documento:
Article